Matsui, Shinichiro
Ri, Chihiro
Bolanos, Lyndsey C. http://orcid.org/0000-0002-5447-5277
Choi, Kwangmin
Shibamiya, Asuka
Ishii, Arata
Takaishi, Koji
Oshima-Hasegawa, Nagisa
Tsukamoto, Shokichi http://orcid.org/0000-0003-4314-893X
Takeda, Yusuke
Mimura, Naoya
Yoshimi, Akihide http://orcid.org/0000-0002-0664-7281
Yokote, Koutaro
Starczynowski, Daniel T. http://orcid.org/0000-0002-5771-7462
Sakaida, Emiko http://orcid.org/0000-0002-7254-1928
Muto, Tomoya http://orcid.org/0000-0002-2345-5572
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (20K22933 and 21H02946)
Mochida Memorial Foundation for Medical and Pharmaceutical Research
SENSHIN Medical Research Foundation
Astellas Foundation for Research on Metabolic Disorders
Naito Foundation
Leukemia and Lymphoma Society
Friends of Leukemia Research Fund
Article History
Received: 26 November 2022
Revised: 31 March 2024
Accepted: 4 April 2024
First Online: 12 April 2024
Competing interests
: D.T.S. serves on the scientific advisory board at Kurome Therapeutics and is a consultant for and/or received funding from Kurome Therapeutics, Captor Therapeutics, Treeline Biosciences, and Tolero Therapeutics. D.T.S. has equity in Kurome Therapeutics. The other authors declare no competing interests.